U.S. Food And Drug Administration extends action date for tofacitinib new drug application by three months
21 August 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for tofacitinib...
List view / Grid view
News
Ariana appoints Dr Mariana Kuras as chief technology officer
21 August 2012 | By ANDREW LLOYD & ASSOCIATES
CTO appointment reinforces senior management expertise in biomarker industry...
Tecan’s new QC Kit for Freedom EVO® workstations released
21 August 2012 | By kdm communications limited
Tecan has launched the QC Kit, a total solution for liquid handling performance verification testing on Freedom EVO® workstations...
Cardio3 BioSciences appoints Dr. Alexander Milstein as Vice President of Clinical Development
21 August 2012 | By Citigate Dewe Rogerson
C3BS announces the appointment of Dr Alexander Milstein...
Abbott announces CE Mark and European launch of next-generation XIENCE Xpedition™ Drug Eluting Stent
20 August 2012 | By Abbott
XIENCE Xpedition™ Everolimus Eluting Coronary Stent System receives CE Mark...
With the New LabRAM HR Evolution, Research Raman is made easy!
17 August 2012 | By HORIBA Scientific
Fully automated extended wavelength range capability and new generation of software offer versatility without compromise...
FDA approves updated prescribing information for Tradjenta® (linagliptin) tablets
17 August 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta® (linagliptin) tablets for use as add-on therapy to insulin.
Biogen Idec Foundation donates $100,000 to launch STEM education collaboration with Teach for America
17 August 2012 | By Biogen Idec
New collaboration in support of Science, Technology, Engineering, and Math education...
Fasha Mahjoor, Phenomenex CEO, to jump off 87th floor of skyscraper
15 August 2012 | By Phenomenex
Fasha Mahjoor, founder and CEO of Phenomenex, will leap off the 87th floor of The Shard in London on the 3rd of September...
Curis and Debiopharm announce initiation of Phase I-II clinical study of HSP90 inhibitor Debio 0932
15 August 2012 | By Maitland
Study to test Debio 0932 in patients with advanced non-small cell lung cancer...
Phase III results show ocriplasmin could be first pharmacological eye treatment for vitreomacular adhesion patients
15 August 2012 | By Novartis
Results of two Phase III studies...
Bristol-Myers Squibb announces specialty pharmacy patient management programs for Sprycel® patients
15 August 2012 | By Bristol-Myers Squibb Company
Patient management programs for Sprycel® patients launched...
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m
15 August 2012 | By GlaxoSmithKline
GSK has reached agreement to divest the majority of its “Classic Brands” in Australia...
Boehringer Ingelheim achieves further growth in first half of 2012
14 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has grown again in the current financial year...
Patheon announces a change to its PDS management structure
13 August 2012 | By Patheon
Patheon Inc. announced that Mark J. Kontny is no longer with the company...
